The ELANE Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population designed to disrupt the ELANE gene in the UM-UC-3 human bladder cancer cell line. This heterogeneous cell pool harbors diverse loss-of-function alleles, providing a population-level gene disruption model without clonal selection artifacts. The CRISPR/Cas9 strategy effectively abolishes neutrophil elastase production, enabling functional studies of ELANE-dependent pathways in a context mimicking tumor heterogeneity.
UM-UC-3 cells, derived from a primary human bladder transitional cell carcinoma, are a well-established model for invasive bladder cancer. They exhibit hallmark features such as robust proliferation, EMT capacity, and high metastatic potential, with a genetic background that includes TP53 mutations. Widely used in xenograft and drug screening studies, these cells provide a clinically relevant platform for investigating bladder cancer biology. The UM-UC-3 line has been extensively characterized and is commonly employed in research on bladder cancer progression and therapeutic response.
ELANE encodes neutrophil elastase, a serine protease that degrades extracellular matrix proteins including elastin, collagen, and fibronectin. It also processes pro-inflammatory cytokines like IL-1?? and TNF, and activates PARs. Upstream regulators include CSF3 (G-CSF), IL-8, and TNF; endogenous inhibitors include SERPINA1 (??1-antitrypsin), SLPI, and elafin. Neutrophil elastase plays critical roles in innate immunity and tissue remodeling, and its dysregulation is implicated in various pathologies. ELANE signaling integrates with PI3K/AKT, MAPK, and JAK/STAT pathways, linking proteolysis to cell survival and proliferation.
In UM-UC-3 bladder cancer cells, ELANE knockout is expected to reduce invasiveness by impairing ECM degradation and inflammatory signaling. This model allows investigation of neutrophil elastase??s role in tumor malignancy, including its impact on migration, Matrigel invasion, and cytokine secretion. By disrupting these processes, researchers can elucidate how ELANE contributes to the metastatic phenotype of transitional cell carcinoma.
Applications include bladder cancer invasion/metastasis studies, protease inhibitor screening, inflammation research, and tumor microenvironment analyses. Compatible assays encompass Western blotting, RT-qPCR, Matrigel invasion, zymography, ELISA, and flow cytometry. The polyclonal knockout background enhances translational relevance by reflecting intratumoral genetic diversity. Contact Ascent Research for validation data, detailed protocols, and ordering information.
